Raymond James Financial
SMMT icon

Raymond James Financial’s Summit Therapeutics SMMT Stock Holding History

Raymond James Financial’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Buy
22,817
+1,913
+9% +$33.9K ﹤0.01% 4764
2026
Q1 		$396K Buy
20,904
+3,053
+17% +$49.4K ﹤0.01% 4509
2025
Q4 		$312K Buy
17,851
+3,743
+27% +$70.4K ﹤0.01% 4549
2025
Q3 		$291K Buy
14,108
+2,416
+21% +$58.6K ﹤0.01% 4433
2025
Q2 		$249K Buy
+11,692
New +$267K ﹤0.01% 4407

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Raymond James Financial's SMMT Position: Q2 2026 in Review

Raymond James Financial increased its Summit Therapeutics (SMMT) stake by 9.2% in Q2 2026, buying an estimated $33.9K and bringing the position to 22,817 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #4764.

Raymond James Financial first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $396K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Raymond James Financial held 22,817 shares of Summit Therapeutics worth $332K as of Q2 2026.
  • Raymond James Financial bought 1,913 Summit Therapeutics shares in Q2 2026, an estimated $33.9K.
  • Summit Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4764 holding.
  • Raymond James Financial first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Raymond James Financial's Summit Therapeutics position peaked at $396K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.